Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure
Background and Aims. Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with promising reduction of HCV infection and disease morbidities. However, unfortunately, treatment failure still occurs in about 5–15% of patients treated with DAA‐based combination reg...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Advances in Virology |
| Online Access: | http://dx.doi.org/10.1155/2020/9075905 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547187968442368 |
|---|---|
| author | Yousry Esam-Eldin Abo-amer Rehab Badawi Mohamed El-Abgeegy Heba Fadl Elsergany Ahmed Abdelhaleem Mohamed Sahar Mohamed Mostafa Hatem Samir Alegaily Shaimaa Soliman Sally Elnawasany Sherief Abd-Elsalam |
| author_facet | Yousry Esam-Eldin Abo-amer Rehab Badawi Mohamed El-Abgeegy Heba Fadl Elsergany Ahmed Abdelhaleem Mohamed Sahar Mohamed Mostafa Hatem Samir Alegaily Shaimaa Soliman Sally Elnawasany Sherief Abd-Elsalam |
| author_sort | Yousry Esam-Eldin Abo-amer |
| collection | DOAJ |
| description | Background and Aims. Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with promising reduction of HCV infection and disease morbidities. However, unfortunately, treatment failure still occurs in about 5–15% of patients treated with DAA‐based combination regimens. The primary aim of the study was to assess the efficacy and safety of a quadruple regimen of (sofosbuvir, daclatasvir, and simeprevir with a weight-based ribavirin) in chronic HCV DAAs-experienced patients. Methods. This observational, open-label prospective study was carried out on 103 genotype 4 hepatitis C virus-infected patients who failed to achieve SVR12 after sofosbuvir-daclatasvir with or without ribavirin. Patients were treated for three months with sofosbuvir (400 mg), daclatasvir (60 mg), and simeprevir (150 mg) with a weight-based ribavirin dosage (1000–1200 mg/d). Response to treatment was determined by quantitative PCR for HCV at 3 months after the end of treatment (SVR12), and adverse events during the treatment were recorded. Results. SVR was achieved in 100 patients (97.1%) at week 12 after treatment. No dangerous or life-threatening adverse events were recorded. Conclusions. Retreatment of HCV genotype 4 patients with quadruple therapy is a good therapeutic option and achieves high response rates with minimal side effects. |
| format | Article |
| id | doaj-art-e3597589afaf4e3fa04ce23f5d9ad256 |
| institution | Kabale University |
| issn | 1687-8639 1687-8647 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Virology |
| spelling | doaj-art-e3597589afaf4e3fa04ce23f5d9ad2562025-02-03T06:45:48ZengWileyAdvances in Virology1687-86391687-86472020-01-01202010.1155/2020/90759059075905Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment FailureYousry Esam-Eldin Abo-amer0Rehab Badawi1Mohamed El-Abgeegy2Heba Fadl Elsergany3Ahmed Abdelhaleem Mohamed4Sahar Mohamed Mostafa5Hatem Samir Alegaily6Shaimaa Soliman7Sally Elnawasany8Sherief Abd-Elsalam9Hepatology, Gastroenterology, and Infectious Diseases Department, Mahala Hepatology Teaching Hospital, Gharbia, EgyptTropical Medicine Department, Tanta University, Tanta, EgyptHepatology and Liver Transplantation Departments, National Hepatology and Tropical Medicine Research Institute, Cairo, EgyptHepatology and Liver Transplantation Departments, National Hepatology and Tropical Medicine Research Institute, Cairo, EgyptHepatology and Liver Transplantation Departments, National Hepatology and Tropical Medicine Research Institute, Cairo, EgyptHepatology and Liver Transplantation Departments, National Hepatology and Tropical Medicine Research Institute, Cairo, EgyptHepatology, Gastroenterology, and Infectious Diseases Department, Benha Faculty of Medicine, Benha, EgyptDepartment of Public Health and Community Medicine, Menofia University, Menofia, EgyptTropical Medicine Department, Tanta University, Tanta, EgyptTropical Medicine Department, Tanta University, Tanta, EgyptBackground and Aims. Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with promising reduction of HCV infection and disease morbidities. However, unfortunately, treatment failure still occurs in about 5–15% of patients treated with DAA‐based combination regimens. The primary aim of the study was to assess the efficacy and safety of a quadruple regimen of (sofosbuvir, daclatasvir, and simeprevir with a weight-based ribavirin) in chronic HCV DAAs-experienced patients. Methods. This observational, open-label prospective study was carried out on 103 genotype 4 hepatitis C virus-infected patients who failed to achieve SVR12 after sofosbuvir-daclatasvir with or without ribavirin. Patients were treated for three months with sofosbuvir (400 mg), daclatasvir (60 mg), and simeprevir (150 mg) with a weight-based ribavirin dosage (1000–1200 mg/d). Response to treatment was determined by quantitative PCR for HCV at 3 months after the end of treatment (SVR12), and adverse events during the treatment were recorded. Results. SVR was achieved in 100 patients (97.1%) at week 12 after treatment. No dangerous or life-threatening adverse events were recorded. Conclusions. Retreatment of HCV genotype 4 patients with quadruple therapy is a good therapeutic option and achieves high response rates with minimal side effects.http://dx.doi.org/10.1155/2020/9075905 |
| spellingShingle | Yousry Esam-Eldin Abo-amer Rehab Badawi Mohamed El-Abgeegy Heba Fadl Elsergany Ahmed Abdelhaleem Mohamed Sahar Mohamed Mostafa Hatem Samir Alegaily Shaimaa Soliman Sally Elnawasany Sherief Abd-Elsalam Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure Advances in Virology |
| title | Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure |
| title_full | Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure |
| title_fullStr | Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure |
| title_full_unstemmed | Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure |
| title_short | Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure |
| title_sort | quadruple therapy offers high svr rates in patients with hcv genotype 4 with previous treatment failure |
| url | http://dx.doi.org/10.1155/2020/9075905 |
| work_keys_str_mv | AT yousryesameldinaboamer quadrupletherapyoffershighsvrratesinpatientswithhcvgenotype4withprevioustreatmentfailure AT rehabbadawi quadrupletherapyoffershighsvrratesinpatientswithhcvgenotype4withprevioustreatmentfailure AT mohamedelabgeegy quadrupletherapyoffershighsvrratesinpatientswithhcvgenotype4withprevioustreatmentfailure AT hebafadlelsergany quadrupletherapyoffershighsvrratesinpatientswithhcvgenotype4withprevioustreatmentfailure AT ahmedabdelhaleemmohamed quadrupletherapyoffershighsvrratesinpatientswithhcvgenotype4withprevioustreatmentfailure AT saharmohamedmostafa quadrupletherapyoffershighsvrratesinpatientswithhcvgenotype4withprevioustreatmentfailure AT hatemsamiralegaily quadrupletherapyoffershighsvrratesinpatientswithhcvgenotype4withprevioustreatmentfailure AT shaimaasoliman quadrupletherapyoffershighsvrratesinpatientswithhcvgenotype4withprevioustreatmentfailure AT sallyelnawasany quadrupletherapyoffershighsvrratesinpatientswithhcvgenotype4withprevioustreatmentfailure AT sheriefabdelsalam quadrupletherapyoffershighsvrratesinpatientswithhcvgenotype4withprevioustreatmentfailure |